We are live on
!
Find out more
AWGLSCP
ABG-WTT Global Life Science Capital Partners Portfolio holdings
AUM
$12.3M
1-Year Est. Return
3.13%
This Fund
S&P 500
This Quarter
Est. Return
-11.78%
1 Year Est. Return
-3.13%
3 Year Est. Return
+108.96%
5 Year Est. Return
-90.91%
10 Year Est. Return
–
AUM
$51.7M
AUM Growth
-$39.9M
(-44%)
Cap. Flow
-$31.4M
Cap. Flow
% of AUM
-60.69%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
–
Reduced
1
Closed
–
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pulmonx
LUNG
|
+$31.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
M
MAMNY
IWM
VH
GBCP
SCI
CCM
MP
ABG-WTT Global Life Science Capital Partners's Q2 2021 Portfolio in Review
As of Q2 2021, ABG-WTT Global Life Science Capital Partners held 2 positions worth $51.7M, down 44% from $91.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
ABG-WTT Global Life Science Capital Partners withdrew a net $31.4M in Q2 2021, reducing 1 holding. Its largest reduction was Pulmonx, cutting an estimated $31.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- ABG-WTT Global Life Science Capital Partners's biggest Q2 2021 reduction was Pulmonx, cutting an estimated $31.4M.
- ABG-WTT Global Life Science Capital Partners's ten largest holdings make up 100% of its $51.7M portfolio in Q2 2021.
- ABG-WTT Global Life Science Capital Partners opened 0 new positions and closed 0 in Q2 2021.
- ABG-WTT Global Life Science Capital Partners's portfolio value fell 44% quarter-over-quarter to $51.7M.
Based on ABG-WTT Global Life Science Capital Partners's 13F filing for Q2 2021, filed 16 Aug 2021.